Switzerland, Germany, France, United Kingdom, United States
Show moreThe company will be in the pharmaceutical domain producing new vaccines, treatment components, and laboratory diagnostic kits. The company is established to help in fighting: 1. TB in humans and bovine by producing Erythra TB diagnostic kit which is simple but provides high sensitivity and specificity. 2. Cancers by producing early detection and monitoring diagnostic kits. 3. COVID-19 by producing a highly sensitive diagnostic kit for measuring the infection load, monitoring treatment, and identifying a complete cure. 4. Other kits for new viruses and infectious disorders can be developed very rapidly once identified. All company products will be highly efficient because they are developed based on a scientific approach based on the concrete understanding of biological processes related to the immune system. The company will control the industry on a monopoly basis. The market size is multi-billion / year, as the population suffering from those diseases is high. The risk will be political influences that can be played by large companies that may be affected.
100% positive feedbacks
70 followers
100% positive feedbacks
29 followers